Arianna Portmann-Baracco

Arianna Portmann-Baracco

Auto-generated profile, based on publicly available information

Arianna Portmann-Baracco

Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJuan Leon-Abarca
Juan Leon-Abarca
APArianna Portmann-Baracco
Arianna Portmann-Baracco
MBMayte Bryce-Alberti
Mayte Bryce-Alberti
CRCarlos Ruiz-Sánchez
Carlos Ruiz-Sánchez
RARoberto Alfonso Accinelli
Roberto Alfonso Accinelli
GGGustavo Francisco Gonzales
Gustavo Francisco Gonzales
Aims: The objective of this study is to analyze how the impact of Diabetes Mellitus [DM] in patients with COVID-19 varies according to altitudinal gradient.Methods: We obtained 1,280,806 records from adult patients with COVID-19 and DM to analyze the probability of COVID-19, development of COVID-19 pneumonia, hospitalization, intubation, admission to the Intensive Care Unit [ICU] and case-fatality rates [CFR]. Variables were controlled by age, sex and altitude of residence to calculate adjusted prevalence and prevalence ratios.Results: Patients with DM had a 21.8% higher prevalence of COVID-19 and an additional 120.2% higher prevalence of COVID-19 pneumonia. The adjusted prevalence was also higher for these outcomes as well as for hospitalization, intubation and ICU admission. COVID-19 and pneumonia patients with DM had a 97.0% and 19.4% higher CFR, respectively. With increasing altitudes, the probability of being a confirmed COVID-19 case and the development of pneumonia decreased along CFR for patients with and without DM. However, COVID-19 patients with DM were more likely to require intubation when residing at high altitude.Conclusions: The study suggests that patients with DM have a higher probability of being a confirmed COVID-19 case and developing pneumonia. Higher altitude had a protective relationship against SARS-CoV-2 infection; however, it may be associated with more severe cases in patients with and without DM. High altitude decreases CFR for all COVID-19 patients. Our work also shows that women are less affected than men regardless of altitude.

1 January 2020 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
PSPatricia Merab Sauñe
Patricia Merab Sauñe
MBMayte Bryce-Alberti
Mayte Bryce-Alberti
APArianna Sibila Portmann-Baracco
Arianna Sibila Portmann-Baracco
RARoberto Alfonso Accinelli
Roberto Alfonso Accinelli
We present two cases of severe COVID-19 that were rejected by medical institutions. The management of the disease was done at home with methylprednisolone (MP) pulse therapy for three days. This resulted in a favorable evolution and resolution of most symptoms. COVID-19 infection presents as asymptomatic disease, non-severe symptomatic disease, and severe respiratory inflammatory disease. The first two forms are dependent on viral response and a “cytokine storm” is responsible for the progression into severe disease. Glucocorticoids (GC) reduce inflammation by different mechanism depending of their concentration. Pulses lead to overall apoptosis of immune cells. Studies using pulse MP as treatment for SARS-CoV-1 showed clinical improvement and decreased incidence of ARDS compared with patients who received low dose steroid treatment. Inhibition of excessive inflammation through timely administration of GC in the early stage of inflammatory cytokine storm effectively prevents the occurrence of ARDS.

4 March 2022 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
GVGerman Valenzuela-Rodriguez
German Valenzuela-Rodriguez
MLMiguel Lescano-Alva
Miguel Lescano-Alva
MBMayte Bryce-Alberti
Mayte Bryce-Alberti
APArianna Portmann-Baracco
Arianna Portmann-Baracco
WPWalter Prudencio-León
Walter Prudencio-León
Objetivo. Conocer las complicaciones cardiovasculares agudas más frecuentes en una población peruana de pacientes oncológicos. Materiales y métodos. Estudio retrospectivo, descriptivo de pacientes oncológicos atendidos en la Clínica Delgado entre enero de 2014 a diciembre de 2019, de los cuales se seleccionó el subgrupo con los siete cánceres más prevalentes a nivel nacional según la información de Globocan 2018. Adicionalmente, se evaluó la epidemiología de los pacientes con complicaciones cardiovasculares que condicionaron su hospitalización o que se detectaron en ella, ponderándose su riesgo cardiovascular según las escalas de Hermann y SCORE. Resultados. Cuarenta y cuatro pacientes tuvieron complicaciones; 27 (61,4%) se hospitalizaron debido a causas cardiovasculares agudas. La edad promedio de este subgrupo fue 69,88 años (DS 12,77) y 22 (81,5%) fueron mayores de 60 años. Catorce (51,9%) fueron de sexo masculino. De acuerdo con la escala de Hermann, un 33,3% tuvo un riesgo intermedio y 14,9% un riesgo alto o muy alto. De acuerdo con la escala SCORE, 62,97% tuvieron un riesgo intermedio y un 7,40% un riesgo alto. Las complicaciones cardiovasculares agudas más comunes fueron trombosis venosa profunda e infarto cerebral isquémico (66,65%). Un paciente (3,7%) reportó enfermedad cardiovascular previa. Cuatro pacientes (14,8%) tuvieron una evolución fatal durante la hospitalización. El tiempo de hospitalización tuvo una mediana de 5 días (4-10). Conclusiones. Se presentan los casos de complicaciones cardiovasculares agudas en una población de pacientes oncológicos y su riesgo cardiovascular según las puntuaciones de Hermann y SCORE. Las complicaciones más frecuentes fueron la trombosis venosa profunda (48,14%), el infarto cerebral (18,51%) y el infarto de miocardio (14,81%).

13 May 2023 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
APArianna S. Portmann-Baracco
Arianna S. Portmann-Baracco
RARodrigo Gerónimo Alcorta-Proaño
Rodrigo Gerónimo Alcorta-Proaño
CNClaudia Nuñez-Mochizaki
Claudia Nuñez-Mochizaki
CWCamille M. Webb
Camille M. Webb
JTJuan Trelles
Juan Trelles
MRMauricio F. La Rosa
Mauricio F. La Rosa
Objective Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery. Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G + , IgM + , or both IgG+ and IgM + . Bivariate and multivariable analyses were performed. Results We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98–36.09; p < 0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65–18.02; p < 0.05). Conclusion We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia. Key Points